/
•
•
The proposed rights issue, at a 90% valuation cut, makes one thing clear: it’s the investors who are calling the shots here.


A public listing will help clean up the hospital chain’s balance sheet after the costly Sahyadri acquisition. But depressed metrics, integration risks and lofty valuations make this far from a clean turnaround story.
The solar module maker’s investors want proof of its durability in the face of a leadership change and a costly push into energy storage.
Mounjaro’s blockbuster debut has already sparked a seismic shift across Indian healthcare, diagnostics and pharma. A marked change in consumer behaviour looks imminent.